Maxim analyst Naz Rahman raised the firm’s price target on Viking Therapeutics to $15 from $10 and keeps a Buy rating on the shares. The analyst now sees a lower risk asset in VK2809 which should have a higher probability of success in Nash as the Phase 2B trial near its first set of data next year. Rahman also points to the activity around the GLP-1s, which are advancing rapidly in obesity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VKTX:
- Madrigal’s data bodes well for Viking’s de-risked VK2809, says BTIG
- Trial success is rocketing this NASH stock higher and sinking these peers
- Madrigal data ‘great readthrough’ for Viking, says H.C. Wainwright
- Viking stands to benefit from Madrigal’s resmetirom results, says William Blair
- Viking Therapeutics up 58% after Madrigal announces NASH trial data